Physician profile
John Arthur Abrams
NPI 1891835294
$3,014.42
in general payments reported to CMS, 2019-2025
32 companies · $492 in 2025
The $492 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $305 · 2020: $556 · 2021: $434 · 2022: $318 · 2023: $492 · 2024: $417 · 2025: $492.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,401.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,401.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $828.24 | 2019-2025 | Farxiga, Airsupra |
| Abbvie INC. | $389.24 | 2021-2025 | Vraylar |
| Pfizer INC. | $234.69 | 2019-2025 | |
| Novo Nordisk INC | $198.13 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $134.41 | 2019-2025 | Mounjaro, Zepbound, Kisunla |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $105.86 | 2019-2025 | Xifaxan, Trulance |
| Janssen Scientific Affairs, LLC | $103.25 | 2022 | |
| Exact Sciences Corporation | $96.96 | 2023-2025 | Cologuard Collection Kit |
| Corium, LLC | $77.76 | 2023-2024 | Azstarys |
| Merck Sharp & Dohme LLC | $76.83 | 2020-2021 | |
| Eisai INC. | $71.76 | 2020-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $61.87 | 2022-2025 | |
| Amgen INC. | $60.70 | 2019-2025 | Otezla, Repatha |
| Glaxosmithkline, LLC. | $60.54 | 2021-2023 | Arexvy, Shingrix, Trelegy Ellipta |
| Idorsia Pharmaceuticals US INC | $47.16 | 2022-2025 | Quviviq |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $46.54 | 2019-2023 | Veozah |
| Phathom Pharmaceuticals, INC. | $46.35 | 2024-2025 | Voquezna |
| Inspire Medical Systems, INC. | $45.72 | 2024 | Inspire |
| Takeda Pharmaceuticals U.S.A., INC. | $38.22 | 2020-2022 | |
| Abbott Laboratories | $37.46 | 2021-2023 | Freestyle Libre 2 |
| Otsuka America Pharmaceutical, INC. | $34.00 | 2025 | Rexulti |
| Paratek Pharmaceuticals, INC. | $28.34 | 2022-2023 | Nuzyra |
| Allergan, INC. | $27.58 | 2019-2020 | |
| Nestle Healthcare Nutrition INC. | $23.32 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.39 | 2019 | |
| Amarin Pharma, INC. | $20.81 | 2019 | |
| Adlon Therapeutics L.P. | $18.11 | 2020 | |
| Daiichi Sankyo INC. | $17.86 | 2024 | Injectafer |
| Corcept Therapeutics | $17.54 | 2024 | Korlym |
| Sanofi-Aventis U.S. LLC | $16.09 | 2020 | |
| Radius Health, INC. | $15.07 | 2024 | Tymlos |
| Janssen Pharmaceuticals, INC | $11.62 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Abrams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.